Table of Contents

To view and print the document you may need to install the latest version of the free Acrobat Reader software. If you do not currently have the latest version please click here.

Johnson & Johnson:
Medical Device & Diagnostics

A time of change and challenge

April 30th 2012

£795 / $1390 / €995

Online, PDF, Print

Johnson & Johnson is a holding company that comprises more than 250 healthcare companies located in 60 countries throughout the world. In terms of revenue, the company claims to be the world’s largest medical device company, the sixth-largest consumer healthcare company, the eighth-largest pharmaceucticals business and the sixth-largest biologics company. The group’s structure is based around three business segments – Medical Devices & Diagnostics, Pharmaceuticals and Consumer.

This report mainly focuses on the activities and performances of Johnson & Johnson’s Medical Devices businesses, which hold the No 1 or 2 market positions in the majority of their markets.

In addition to advancing its product pipelines through internal development, alliances or significant equity investments, Johnson & Johnson has acquired several companies to enhance the growth and create long-term value for its Medical Devices & Diagnostics business. Typical examples include the acquisitions of: Micrus Endovascular, a developer and manufacturer of minimally-invasive devices for haemorrhagic and ischaemic stroke; Finsbury Orthopaedics, a manufacturer and global distributor of orthopaedic implants; Acclarent, a medical technology company dedicated to designing, developing and commercialising devices that address conditions affecting the ear, nose and throat; Gloster Europe, a developer of area-decontamination technologies to help prevent healthcare-acquired infections; Mentor, a supplier of medical products for the aesthetic market; and SterilMed, a reprocessor of surgical instruments.

In addition, at the time of the publication of this report, Johnson & Johnson was awaiting final regulatory clearance in the US to complete its largest acquisition to date - that of Synthes to strengthen its leadership position in orthopaedics.

In recent years, Johnson & Johnson has divested several businesses that it considered to be outside the scope of its future growth platforms. These include Ethicon Endo-Surgery’s Breast Care division in 2010; Ethicon’s Professional Wound Care division in 2008; and Codman & Shurtleff's Surgical Instruments business in 2011. Furthermore, at the end of 2011, Cordis discontinued its clinical development programme for the Nevo Sirolimus-eluting coronary stent and ended the manufacture of Cypher drug-eluting stents due to market and competitive pressures. In 2009, the group's Independence Technology subsidiary ceased sales and marketing of its principal product, the iBOT Mobility System, as demand for the system had not proven sufficient to create a sustainable market.

Towards the end of 2011, Johnson & Johnson began re-organising its Medical Devices & Diagnostics segment into three, more integrated, global businesses:

This re-organisation is designed to help increase Johnson & Johnson’s focus on strategic areas for growth and address unique customer needs at a time of significant change in the healthcare industry.

In 2011, the Medical Devices & Diagnostics business generated sales of US$25.8 billion, representing 40% of the Johnson & Johnson group's revenue.

Separate profiles are published on the following Johnson & Johnson Medical Devices & Diagnostics subsidiaries – Cordis (including Biosense Webster), DePuy, Ethicon, Ethicon Endo-Surgery, LifeScan and Vistakon.

Available as a comprehensive 212-page single report or as individual J&J companies

Detailed contents for each J & J report

  • Key contact information
  • Introduction to the company and its current activities
  • Summary of its financial performance
  • Who are the company’s major competitors?
  • Key recent events in an “at a glance” format
Financial Review
  • Current year and annual financial data, including revenue breakdowns by product area and geographic region (if available)
  • Table providing in-depth five-year financial analysis
  • Employee data, including breakdown by company division and geographic location

Strategic Focus
Investigates the company’s aims and its areas of focus

Core product areas, key brands, product approvals and launches
Research and Development
  • How much has been invested in R&D?
  • Where is the research based?
  • What alliances and agreements does the company have and with whom?

Manufacturing and Distribution
  • Identifying the company’s manufacturing locations
  • Sales and marketing facilities

  • With whom has the company reached agreements and what do they involve?

Mergers, Acquisitions and Divestments

Key Corporate Events